In this study, the long-term outcome of 1818 patients treated in five consecutive clinical trials (the cooperative study group for childhood acute lymphoblastic leukaemia (COALL) 82, 85, 89, 92 and 97) from 24 cooperating centres in Germany is reported. The probability of event-free survival (pEFS) improved significantly from the first two trials conducted in the 1980s (COALL 82 and COALL 85) to the three trials conducted in the 1990s (COALL 89, 92 and 97) (P ¼ 0.001). Through all COALL studies, age X10 years and initial white blood cell count (WBC) X50 Â 10 9 /l and pro-B immunophenotype were of significant prognostic relevance. A refinement of risk assessment has been achieved by in vitro drug sensitivity testing in COALL 92 and 97. In patients with very sensitive leukaemic cells, therapy could be reduced without loss of efficacy. In COALL 97, a further improvement in risk stratification was gained by the molecular assessment of minimal residual disease (MRD) under treatment, which proved to have a superior prognostic effect when compared with in vitro drug sensitivity testing. Importantly, the gradual reduction in central nervous system (CNS) irradiation led to a decreased incidence of brain tumours as a second malignancy. In general, the prevention of treatmentrelated late effects will be one of the major issues in future studies. It remains to be shown whether prolonged infusions of anthracyclines, which have been implemented into the COALL studies after equal efficacy compared with short-time infusions was confirmed, will be associated with fewer cardiac late effects. Another way to prevent late effects may be a more refined risk assessment allowing for a reduction in cumulative treatment burden. A great challenge in the future will be to improve the overall treatment results, which very likely can only be achieved by the identification of molecularly defined subgroups to which novel, rational therapeutic strategies can be applied.
Introduction
Since 1980, when the cooperative study group for childhood acute lymphoblastic leukaemia (COALL) studies were initiated, seven trials have been conducted. The aim of the first three trials was to define risk criteria of acute lymphoblastic leukaemia (ALL) of childhood by combining the first known risk factor, initial white blood cell count (WBC), with the variables age at diagnosis, immunophenotype and chromosomal rearrangements to establish and optimize a risk-adapted treatment approach. [1] [2] [3] In COALL 92, the in vitro drug sensitivity, which was determined using the methyl-thiazol-tetrazolium assay, was prospectively evaluated and implemented in COALL 97 as a new risk variable. 4 COALL 92 also focussed on the mode of administration of anthracyclines and on the drug of choice in maintenance therapy. 5, 6 The reduction in central nervous system (CNS) irradiation has been an important issue in all trials. The cutoff for the WBC as an indication for CNS irradiation was gradually increased in patients with B-precursor ALL. Overall, only a minority of patients now receive prophylactic irradiation of the CNS, and the incidence of brain tumours as second malignancy has decreased substantially.
Patients and methods
Between 1982 and 2003, 1967 patients o18 years with newly diagnosed ALL were enrolled in five consecutive treatment protocols (COALL 82, 85, 89, 92 and 97) from 24 cooperating centres in Germany. Patients were excluded because of previous treatment, other additional treatment, ALL as a second malignancy (second malignant neoplasm (SMN)), or other major medical conditions preventing therapy according to the protocol (n ¼ 102). In the COALL 89 and 92 trials, patients o1 year of age at diagnosis were treated with various regimens and during the COALL 97 study period patients o1 year of age at diagnosis were treated according to the international Interfant study. Hence, all 47 infant patients during the study periods 82 through 97 were excluded from the analysis, summing up to a total of 1818 patients who were analysed in this report.
The studies were approved by the ethics committee of the University of Hamburg and institutional review boards of individual trial centres. Informed consent was obtained from parents or guardians in each case.
The risk stratification was based on age, white blood cell count, immunophenotype, the response to induction treatment and chromosomal rearrangements. In study 97, a second risk stratification was applied according to the results of the in vitro drug sensitivity testing.
Treatment
Details of treatment have been described in earlier publications 1-3,7-9 (see also Supplementary Table 1 ). In study COALL 82, a reduction in therapy intensity was performed for the first time in patients who were defined as low risk (LR) by an initial WBC of o25 Â 10 9 /l and c-ALL immunological subtype. Cyclophosphamide was replaced with intermediate-dose methotrexate (1 g MTX/24 h; leucovorin 15 mg/m 2 at 48 and 54 h after start of infusion) in consolidation therapy and the reinduction was omitted for these patients. 2 Furthermore, in LR patients with an initial WBC of o3 Â 10 9 /l, cranial irradiation was replaced with six doses of intrathecal MTX, whereas in all other patients CNS irradiation was administered in an age-and risk-adapted dose (15-24 Gy) without intrathecal MTX. In six out of 129 patients (5%), prophylactic CNS irradiation could be omitted. High-risk (HR) patients received intermediate-dose MTX that was added to cyclophosphamide during consolidation and the reinduction was intensified by the addition of teniposide, cytarabine and 6-thioguanine (6-TG).
In the COALL 85 trial, the patient age was implemented as an additional risk factor, allocating patients 410 years at diagnosis to the high-risk group. 2 Systemic therapy for LR patients in COALL 85 was identical with study 82. Patients were excluded from CNS irradiation, when the initial WBC was o5 Â 10 9 /l. For HR patients a combination of high-dose cytarabine (four doses of cytarabine 3 g/m 2 every 12 h) with asparaginase (2 Â 45 000 U/m 2 ASP) was introduced and a randomization of slow versus rapid rotation of six non-crossresistant drug combinations was performed during the consolidation phase. This randomization was stopped in COALL 89 because of inferior results in the rapid rotation arm for patients with 4100 Â 10 9 /l WBC. 8, 9 Owing to the high incidence of relapses in the LR groups of study COALL 82 and 85, the treatment for this group was again intensified by adding teniposide, ASP and 6-TG in consolidation therapy in analogy to the HR protocol and by reintroduction of the reinduction therapy. The upper limit dosage for the prophylactic irradiation was reduced from 24 to 18 Gy.
In COALL 92, the infusion time of daunorubicin was randomized in a therapeutic window, given either as a 1-hour or a 24-h infusion as a pre-phase, evaluating the in vivo leukaemic cell death. During maintenance therapy patients were randomized for either 6-mercaptopurine (6-MP) or 6-TG. The dosage for the prophylactic irradiation was further reduced to 12 Gy for all patients receiving irradiation. Until 1994, all HR patients were eligible for CNS irradiation. In 1994 the inclusion criteria for CNS irradiation were defined as a WBC of 450 Â 10 9 /l in B-progenitor ALL, whereas patients with T-cell ALL (T-ALL) received a cranial irradiation irrespective of the WBC. Overall, a prophylactic CNS irradiation was performed in 29% of the patients.
A second risk stratification according to the results of the in vitro drug sensitivity testing was implemented in COALL 97. For each patient a three-drug resistance analysis was performed, combining the results of the sensitivity to prednisolone, vincristine and ASP in a PVA score, with a high sensitivity towards a drug scored as 1, an intermediate sensitivity scored as 2 and a resistance scored as 3 for each individual drug. Combining the separate scores of each drug resulted in an individual PVA score that varied between 3 (sensitive to all three drugs) and 9 (resistant to all three drugs).
Low-risk patients either received a less intensive treatment (scores 3 and 4; LR reduced), the standard protocol (scores 5 and 6; LR standard) or an intensified treatment according to the HR standard protocol (score 7-9; LR intensified). HR patients either received a less intensive treatment (scores 3 and 4; HR reduced), or the standard protocol (scores 5-9, HR standard) with the recommendation for a haematopoietic stem cell transplantation in patients with scores 8 and 9, provided that a matched sibling donor was available. Patients in whom the score could not be determined were allocated to LR or HR standard therapy, respectively.
A treatment reduction in low-risk-reduced and high-risk-reduced patients was performed by halving the doses of adriamycin and dexamethasone in reinduction. Only 19% of the patients received 12 Gy prophylactic CNS irradiation because of a T-cell immunophenotype or, in case of B-precursor ALL, a WBC of 4200 Â 10 
Statistical analysis
The probabilities of event-free survival (pEFS) and disease-free survival (pDFS) were estimated using the Kaplan-Meier life table analysis and compared between subgroups using the log-rank test. 10 pEFS was defined as the time from diagnosis to the first outcome event, which were remission failure (no remission until day 56), induction death, relapse, death by any cause in remission or a second malignancy. pDFS was defined as the time from complete remission (CR) to first relapse. For patients who achieved CR, cumulative incidence functions of isolated CNS or any (isolated and combined) CNS relapse as well as testicular relapse, therapy-related second malignancies and toxicity-related death were calculated using the method of Kalbfleisch and Prentice and compared with each other using Gray's test. 11, 12 For multivariate analysis of pEFS a Cox regression analysis was performed. The models for multiple analyses included age (cutoff 10 years), WBC (cutoff 50 Â 10 9 /l), immunophenotype, HR criteria (induction failureFno remission at day 29For critical chromosomal translocation) and in vitro drug resistance as covariates. All analyses were performed on the basis of 'intend to treat'. The status of patients was monitored annually on protocol-specific forms and reviewed before data entry by the trial data centre, which also performed the statistical analysis. A recent update of the database (1 September 2008) has been used for this analysis.
Results
Protocol-specific treatment outcome COALL 82. Of 129 evaluable patients enrolled, the 15-year probability of EFS and overall survival was 47. 8±4.4 and 61.4 ± 4.4%, respectively ( Figure 1 ). The median follow-up time of the patients remaining alive (n ¼ 81) is 16.76 years.
The cumulative risk estimate for any CNS relapse was 10.9±2.8%, and was 9.3±2.6% for isolated CNS relapses ( Figure 1) . Notably, none of the LR patients, including those for whom CNS radiation was omitted, developed a CNS relapse.
Three patients developed acute myeloid leukaemia (AML) as a second malignancy and in one patient a thyroid carcinoma was diagnosed. The cumulative incidence of SMN is 3.2 ± 1.6% for all patients. None of the patients in the LR group developed SMN.
COALL 85. The probability of EFS and overall survival among the 289 enrolled patients was 64.2 ± 2.9 and 76.5 ± 2.5% at 15 years, respectively ( Figure 2 ). The median follow-up time of the patients remaining alive (n ¼ 229) is 13.65 years.
The cumulative risk of any CNS relapse was 4.7±1.2%, and was 2.3 ± 0.9% for an isolated CNS relapse (Figure 2) .
In two patients (0.69%) stem cell transplantation in first CR was performed because of induction failure.
The cumulative risk of SMN was 3.8±1.3% after 15 years, which was the highest rate in all COALL studies. In all, 10 patients developed an SMN (four glioblastomas, two lymphoblastic lymphomas, one Hodgkin's disease, two carcinomas and one AML) evenly distributed in the LR and HR B-precursor patients. There has been no T-cell ALL (T-ALL) patient in the COALL 85 study who developed an SMN so far.
COALL 89. At 10 years, the probability of EFS and overall survival among the 205 enrolled patients was 75.6 ± 3.9 and 82.2±2.7%, respectively. The median follow-up time of the patients remaining alive (n ¼ 169) is 11.74 years ( Figure 3) .
The cumulative risk of any CNS relapse was 2.6±1.1% and was 1.1 ± 0.8% for isolated CNS relapses ( Figure 3 ).
In two patients (0.97%), stem cell transplantation in first CR was performed because of induction failure.
Three B-precursor ALL patients developed an SMN (one each with Hodgkin's lymphoma, glioblastoma and B-lymphoblastic lymphoma). The cumulative incidence of SMN after 10 years is 1.5 ± 0.9%. COALL 92. Among the 521 enrolled patients, the probability of EFS and overall survival was 73.2 ± 2.0 and 81.1 ± 1.8% at 10 years, respectively. The median follow-up time of the patients remaining alive (n ¼ 426) is 10.02 years ( Figure 4) .
The cumulative risk of any CNS relapse was 3.9 ± 0.8% and 2.7±0.7% for isolated CNS relapses ( Figure 4 ).
In 15 patients (2.8%), a stem cell transplantation in first CR was performed (n ¼ 8 patients with induction failure; and n ¼ 7 patients with Philadelphia-positive ALL).
In eight patients, a second malignancy was diagnosed (two AML, two osteosarcomas, two glioblastomas, one adenocarcinoma and one Hodgkin's disease) including four patients with T-ALL. The cumulative incidence of second malignancies for all patients is 1.9±0.7% after 10 years.
COALL 97. The probability of EFS and overall survival among the 667 enrolled patients was 76.7 ± 1.7 and 85.4 ± 1.4% at 5 years, respectively. The median follow-up time of the patients remaining alive (n ¼ 568) is 6.64 years ( Figure 5 ).
The cumulative risk of CNS relapse was 4.0±0.8%, and was 2.1 ± 0.6% for isolated CNS relapses ( Figure 5 ).
In 26 patients (3.8%), a stem cell transplantation in first CR was performed (17 patients with induction failure, two patients with evidence of t(4;11) and six patients because of Philadelphia-positive ALL). Probability of event-free survival, overall survival and cumulative incidence of isolated or any central nervous system (CNS) relapse in cooperative study group for childhood acute lymphoblastic leukaemia (COALL) study 92. Figure 1 Probability of event-free survival, overall survival and cumulative incidence of isolated or any central nervous system (CNS) relapse in cooperative study group for childhood acute lymphoblastic leukaemia (COALL) study 82.
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In all, six patients developed a second malignancy (two with AML, and one each with myelodysplastic syndrome, glioblastoma, osteosarcoma and T-lymphoblastic lymphoma), five of whom were patients with T-ALL at initial diagnosis. One additional patient developed a Langerhans cell histiocytosis and was included among patients with SMN. Thus, the overall cumulative incidence of second malignancies is 1.1 ± 0.4% after 10 years (Table 1) .
Treatment results according to presenting features Traditional risk factors. Through all COALL studies, ageX10 years and initial WBC X50 Â 10 9 /l and Pro-B immunophenotype were of significant prognostic relevance in spite of intensified therapy (Table 2 ). In addition, in studies COALL 89, 92 and 97, the pEFS and survival of patients with T-cell phenotype differed significantly from patients with B-precursor ALL (Tables 5-7) . This difference is due to a higher incidence of remission failures (as determined on day 56 of therapy), treatment-related mortality after stem cell transplantation performed in patients with induction failure (as determined on day 29) and a greater number of SMNs, but not due to an increased risk of relapse (pDFS for B-precursor 0.78±0.01 vs 0.76 ± 0.04 for T-ALL patients). Owing to the small number of patients with pro-B ALL this subgroup was not analysed in the individual studies.
A statistically significant prognostic influence of gender could only be shown in COALL 97, and a trend towards better outcome for female patients was also observed in the former studies, except for study COALL 89 in which boys seemed to have a better prognosis. There was no imbalance in patient characteristics between girls and boys.
Risk factors for an isolated CNS relapse were a high leukocyte count (X100 Â 10 9 /l) at diagnosis and a T-cell immunophenotype. In B-precursor ALL, the incidence of relapses with CNS involvement is not significantly different in patients with a WBC above this threshold (0.04 vs 0.06, P ¼ 0.23), whereas it is the case for T-ALL patients (0.03 vs 0.12, P ¼ 0.003). A trend is also noted for isolated CNS relapse in T-ALL but the difference was not significant (0.03 vs 0.08, P ¼ 0.052).
There are no data of chromosomal translocations available in studies COALL 82, 85 and 89. In COALL 92 and 97, an adverse prognostic significance of the BRC/ABL translocation could be shown.
In COALL 97, data on TEL/AML1 fusion were available for the majority of the patients and a favourable prognostic outcome for TEL/AML1-positive patients could be shown (pEFS 71.0 ± 2.5 vs 85.4±3.5 P ¼ 0.001). A statistically significant difference, however, was evident in the HR group (pEFS 64 ± 3 vs 89 ± 5; P ¼ 0.024) but not in the LR group (pEFS 81±3 vs 82±5; P ¼ 2.58).
Prednisolone, vincristine and asparaginase (PVA) score. The difference in 10-year EFS between PVA scores 3 and 4 (pEFS 0.80 ± 0.03) and scores of 8 and 9 (pEFS 0.63±0.08) is statistically significant (P ¼ 0.042; Figure 6 ). This is due to a worse prognosis in HR patients with scores 8 and 9 (pEFS 0.47±0.11) but not in LR patients with scores 8 and 9
Figure 5 Probability of event-free survival, survival and cumulative incidence of isolated or any central nervous system (CNS) relapse in cooperative study group for childhood acute lymphoblastic leukaemia (COALL) study 97. Abbreviations: COALL, cooperative study group for childhood acute lymphoblastic leukaemia; CNS, central nervous system; CR, complete remission.
Long Abbreviations: COALL, cooperative study group for childhood acute lymphoblastic leukaemia; pEFS, probability of event-free survival; T-ALL, T-cell ALL; WBC, white blood cell count. *P-value was calculated for PRO-B vs T-ALL and B-precursor. Abbreviations: CNS, central nervous system; COALL, cooperative study group for childhood acute lymphoblastic leukaemia; NCI, National Cancer Institute; EFS, event-free survival; T-ALL, T-cell ALL; WBC, white blood cell count.
Long-term results of cooperative ALL trials G Escherich et al study. 14 As T-ALL often shows a delayed MRD kinetic, the assessment of MRD was performed separately in T-ALL and B-precursor ALL.
At the end of induction, the evaluation of MRD identified distinct groups in B-precursor and T-ALL patients with a favourable and an adverse prognosis (B-precursor: 10-year-pEFS 0.92±4.0 for MRD-negative vs 0.71±5.0 for MRD-positive patients; T-ALL: 10-year-pEFS 0.81 ± 7.0 for MRDo10 À3 vs 0.48±8.0 for patients with MRDX10 À3 ). The group with a high MRD load X10
À3 at the end of induction comprised a substantial part of the patients, who were already identified morphologically as induction failure (7/42 B-precursor and 12/ 39 T-ALL patients). At week 12 in LR patients and week 15 in HR patients, respectively, only very few patients (6% B-precursor ALL and 12% T-ALL patients) still had measurable MRD levels. Therefore, we introduced a third time point of MRD evaluation at week 7, after a first cycle of intensification therapy, which identified a group with a very high risk of relapse in T-ALL patients ( Table 7) .
The comparison of MRD results with the PVA score showed that the prognostic effect of the PVA score is inferior to the MRD measurement at defined time points. By multivariate analysis, low MRD levels at the end of induction (week 5) predicted a greater pDFS independently of the PVA score (MRD P ¼ 0.002 vs PVA P ¼ 0.09) in T-ALL. In contrast, these parameters were not completely independent from each other at this early time point in B-precursor-ALL (MRD P ¼ 0.059 vs PVA P ¼ 0.063), but they became independent at week 7 after one cycle of intensive therapy (MRD P ¼ 0.018 vs PVA P ¼ 0.253).
Treatment results according to randomized questions
In study COALL 92, the use of 6-TG in maintenance therapy offered no advantage when compared with 6-MP. 5 The DFS is equal after a median observation time of 13.2 years (pDFS for both groups 0.79 ± 0.03). In contrast, the EFS is different because of two second malignancies and one death after an accident in the 6-TG group, however, without reaching statistical significance.
The in vivo response to daunorubicin after a single 1-h or 24-h infusion was analysed by daily measurements of WBC and centrally, manually differentiated peripheral blood smears. The leukaemic burden was equally reduced in both randomized arms as measured on day 7 after anthracycline therapy. Set at 100% the blast cell count at diagnosis was reduced by 99.4% in the 1-h group versus 98.9% in the 24-h infusion group (NS). The Hodges-Lehmann estimate of the difference was 0.12 (95% confidence interval for the difference was 0.10-1.1%). KaplanMeier analysis showed an equal probability of EFS for the short time and prolonged time infusion groups (24 h: 83%±5; 1 h: 81 ± 6) after a median observation time of 12.3 years. There was also no significant difference when LR and HR patients were analysed separately. Abbreviations: CNS, central nervous system; COALL, cooperative study group for childhood acute lymphoblastic leukaemia; NCI, National Cancer Institute; EFS, event-free survival; T-ALL, T-cell ALL; WBC, white blood cell count.
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Discussion
In trial COALL 82, the replacement of CNS irradiation with intrathecal MTX seemed to be feasible to prevent CNS relapses. Upon increasing the doses of intrathecal MTX, irradiation could gradually be omitted in the majority of B-precursor ALL patients. The proportion of patients with CNS irradiation could be stepwise reduced from 95% in study COALL 82 (COALL 85: 91%; COALL 89: 57%; and COALL 92: 32%) to 19% in COALL 97 without the expense of a higher incidence of CNS relapses. The dosage for prophylactic irradiation was also substantially lowered from 15-24 Gy in COALL 82 to 12 Gy in COALL 92 and 97. Brain tumours as a second malignancy became a rare event with only three out of 1186 patients in trials 92 and 97. A further reduction in CNS irradiation has been introduced in the current COALL 03 trial. CNS irradiation is being omitted for the very first time in T-ALL patients with an initial WBC of o50 Â 10 9 /l. A higher cutoff of WBC (for example, X100 Â 10 9 /l) may still be safe as shown by the results of the BFM/Associazione Italiana Ematologia Oncologia Pediatrica study group. 15 In COALL trials, medium-dose MTX (1 g/m 2 ) was used instead of high-dose MTX (5 g/m 2 ) and all patients received at least one cycle of high-dose cytarabine and repetitively high doses of ASP that led to a prolonged depletion of asparagine in the CSF. 16 Both treatment elements may compensate for the use of highdose MTX.
Second malignancies are serious long-term sequels after treatment of childhood ALL. In the COALL studies the incidence ranged between 3.8 ± 1.3% and 1.1 ± 0.4% in COALL 85 and COALL 97, respectively. Beside cranial irradiation, several drugs have been implicated in causing second malignancies. 17 Moreover, the more frequent application of stem cell transplantation is expected to additionally increase the risk of second malignancies. 18 In study COALL 92 and 97, the proportion of patients developing an SMN is significantly higher in T-ALL than in patients with B-precursor ALL (P ¼ 0.001). Out of 165 T-ALL patients, nine (5.2%) developed an SMN compared with 6 out of 1005 B-precursor patients (0.59%). In these studies, only two of nine T-ALL patients developed a glioblastoma, whereas six SMNs were of haematological origin and one SMN was an extra-cranial solid tumour. In contrast, in the predecessor COALL studies 82, 85 and 89, the second malignancies in T-ALL patients were brain tumours exclusively. Treatment of HR patients did not differ between T-ALL and B-precursor ALL, except for the indication for CNS irradiation. There was also no Long-term results of cooperative ALL trials G Escherich et al major difference in the treatment backbone between studies COALL 85/89 and COALL 92/97. A higher incidence of SMN in T-ALL patients was also observed in other studies, without indication of tumour entity. 19 This phenomenon may be explained by chance due to the small number of events rather than by a specific underlying defect, for instance, in immunological tumour surveillance or DNA repair, although the latter cannot be excluded given the sparse data available.
COALL 92 was the first study to introduce a randomization of 6-MP and 6-TG in maintenance therapy, as a higher clinical efficacy of 6-TG was postulated due to a more direct conversion into the intracellular thioguanine nucleotides. Although thioguanine nucleotides were seven times higher in the 6-TG group compared with the 6-MP group, 20 6-TG was not more effective than 6-MP. Therapy with 6-TG was more often complicated by prolonged myelosuppression and especially thrombocytopenia. 5 As a consequence, 6-MP has remained the preferred drug for maintenance therapy. Veno-occlusive disease, as reported in other studies, 21, 22 did not occur in COALL patients. This was also true for trial ALL-REZ 90 for relapsed patients, in which 6-TG was used together with weekly intravenous MTX in maintenance therapy (G Henze, personal communication). No vincristine/prednisone pulses or delayed intensifications were applied in the maintenance therapy in COALL trials as well as in the ALL-REZ 90 study. This might explain the varying incidence of veno-occlusive disease.
Cardiac damage due to anthracyclines is a major long-term sequel after treatment for ALL at childhood. Prolonged infusions of anthracyclines are less cardiotoxic; 23, 24 however, it had not been analysed whether the in vivo leukaemic cell kill is equivalent to short-term infusions. Therefore, in COALL 92, patients were randomized receiving a single dose of 36 mg/m 2 daunorubicin, either as a 1-h or a 24-h infusion in a therapeutic window, before the start of induction treatment. It was shown that a 24-h and a 1-h infusion were equally cytotoxic to ALL cells. 6 Consequently, since 1994 the infusion time has been set to 24 h for all anthracycline applications. Future analyses are needed to evaluate the long-term effect of this mode of application on cardiac function in childhood cancer survivors.
In the early 1990s, several studies showed the prognostic value of drug resistance profiles for patients with ALL. [25] [26] [27] [28] [29] In COALL 92, the prognostic effect of in vitro drug sensitivity testing towards prednisolone, vincristine and ASP (PVA score) was evaluated. 4 In COALL 97, the PVA score was used for a second stratification allocating patients either to a reduced, standard or intensified therapy. A reduction in therapy was Abbreviations: CNS, central nervous system; COALL, cooperative study group for childhood acute lymphoblastic leukaemia; NCI, National Cancer Institute; EFS, event-free survival; T-ALL, T-cell ALL; WBC, white blood cell count.
Long-term results of cooperative ALL trials G Escherich et al possible without loss of efficacy for patients with a sensitive profile, identified by in vitro drug testing. The prognostic value of the PVA score could only be confirmed for the HR B-precursor patients. With longer follow-up of the original COALL 92 cohort, it became apparent that the PVA score predicted early rather than late relapses, resulting in a decrement in the prognostic power over time. 30 This might be one of the most important reasons why the PVA score still remains a prognostic factor in HR patients, in whom early relapses are predominant, but no longer in LR patients. Abbreviations: CNS, central nervous system; COALL, cooperative study group for childhood acute lymphoblastic leukaemia; MRD, minimal residual disease; NCI, National Cancer Institute; EFS, event-free survival; T-ALL, T-cell ALL; WBC, white blood cell count. Figure 6 Event-free survival according to stratification by in vitro sensitivity towards prednisolone, vincristine and asparaginase in cooperative study group for childhood acute lymphoblastic leukaemia (COALL) study 97.
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